Education
About Us
Working with TipRanks
Follow Us
Heart Test Laboratories, Inc. (HSCS)
NASDAQ:HSCS
HSCS Stock Chart & Stats
$3.44
-$0.05(-1.44%)
At close: 4:00 PM EST
$3.44
-$0.05(-1.44%)
Day’s Range― - ―
52-Week Range$2.01 - $6.47
Previous CloseN/A
Volume8.49K
Average Volume (3M)58.86K
Market Cap
$8.20M
Enterprise Value-$1.07B
Total Cash (Recent Filing)$1.95M
Total Debt (Recent Filing)$876.24K
Price to Earnings (P/E)―
Beta1.42
Next Earnings
Mar 12, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.84
Shares Outstanding3,178,207
10 Day Avg. Volume93,774
30 Day Avg. Volume58,857
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)16.05
Price to Sales (P/S)757.08
P/FCF Ratio-0.44
Enterprise Value/Market Cap-130.05
Enterprise Value/Revenue-123.01K
Enterprise Value/Gross Profit18.17K
Enterprise Value/Ebitda131.84
Forecast
1Y Price Target
$10.60Price Target Upside208.14% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-4.03
Revenue Forecast (FY)$52.15K
Bulls Say, Bears Say
Bulls Say
Financial OutlookThe new price target of $9.20 stems from NPV analysis and represents 3x upside from current prices.
Market PotentialA multi-billion-dollar opportunity exists for its cloud platform, MyoVista Insights, to manage hospital ECGs.
Product LaunchHeartSciences is in the early stages of launching the MyoVista Insight's ECG Platform, which is creating a large market opportunity.
Bears Say
Cash Flow ChallengesThe company will need to raise substantial cash to finance its expected monetization phase following FDA approvals.
Dilution RiskShare count dilution and execution challenges are seen as the biggest risks to the price target.
Financial AdjustmentsThe price target has been reset to $9 from $15, reflecting the impact of share-count dilution on the net present value analysis.
Heart Test Laboratories, Inc. News
HSCS FAQ
What was Heart Test Laboratories, Inc.’s price range in the past 12 months?
Heart Test Laboratories, Inc. lowest stock price was $2.01 and its highest was $6.47 in the past 12 months.
What is Heart Test Laboratories, Inc.’s market cap?
Heart Test Laboratories, Inc.’s market cap is $8.20M.
When is Heart Test Laboratories, Inc.’s upcoming earnings report date?
Heart Test Laboratories, Inc.’s upcoming earnings report date is Mar 12, 2026 which is in 73 days.
How were Heart Test Laboratories, Inc.’s earnings last quarter?
Heart Test Laboratories, Inc. released its earnings results on Dec 11, 2025. The company reported -$0.845 earnings per share for the quarter, missing the consensus estimate of -$0.77 by -$0.075.
Is Heart Test Laboratories, Inc. overvalued?
According to Wall Street analysts Heart Test Laboratories, Inc.’s price is currently Undervalued.
Does Heart Test Laboratories, Inc. pay dividends?
Heart Test Laboratories, Inc. does not currently pay dividends.
What is Heart Test Laboratories, Inc.’s EPS estimate?
Heart Test Laboratories, Inc.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Heart Test Laboratories, Inc. have?
Heart Test Laboratories, Inc. has 3,178,207 shares outstanding.
What happened to Heart Test Laboratories, Inc.’s price movement after its last earnings report?
Heart Test Laboratories, Inc. reported an EPS of -$0.845 in its last earnings report, missing expectations of -$0.77. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Heart Test Laboratories, Inc.?
Currently, no hedge funds are holding shares in HSCS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Heart Test Laboratories, Inc.
Heart Test Laboratories, Inc. (HSCS) is a healthcare technology company specializing in the development and commercialization of advanced cardiovascular diagnostic solutions. The company operates in the medical device sector, focusing on innovative cardiac testing technologies that enhance the ability to assess heart health quickly and accurately. HSCS's core products include non-invasive heart monitoring systems and diagnostic software designed for use in both clinical and remote settings, aiming to improve patient outcomes and streamline cardiology workflows.
HSCS Stock 12 Month Forecast
Average Price Target
$10.60
▲(208.14% Upside)
Technical Analysis
Strata Skin Sciences
―
Biomerica
―
PAVmed
―
Tenon Medical, Inc.
―
Autonomix Medical, Inc.
―
Ownership Overview
2.49% Insiders
0.36% Mutual Funds
4.17% Other Institutional Investors
92.93% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---